Validity and Renewal of Medical Device Registrations in Tanzania

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Tanzania’s rules on how long a licence lasts are built on three numbers, and they are scattered across different documents:

ItemNumberSource
Validity of the registration certificate5 years (from the date of issue, unless suspended or cancelled earlier, and subject to payment of the prescribed annual retention fee)GN 315, regulation 17(1)
Validity of a notification (listing) approval3 yearsCompendium of Guidelines 2024, Part I §5.1
Timing of the renewal applicationAt least 90 days before expiryGN 315, regulation 17(4)
Grace period for renewal90 days after expiryGN 315, regulation 17(5)

At the same time, the validity of a registration certificate is subject to three continuing conditions (Part I §5.1): a) payment of the annual retention fee under the current fee regulations; b) submission of PMS reports; c) submission of reports on adverse effects related to the use of the device. If any one of the three is missing, the certificate, although nominally still within its validity period, is in substance exposed to suspension or cancellation under regulation 18.

Companies that only remember one number — the five-year registration term — frequently miss the parallel three-year cycle that applies to listed products, and they treat the two 90-day windows as a single 180-day buffer. Both reading errors are expensive. The rest of this article explains why the rules must be read in parallel, what the renewal dossier must contain, and which administrative omissions most commonly cost manufacturers their certificates.

2. Legal basis

InstrumentReference / numberPublication dateProvisions
The Tanzania Food, Drugs and Cosmetics (Control of Medical Devices) Regulations, 2015GN. No. 31531 July 2015Regulations 17(1), 17(2), 17(3), 17(4), 17(5), 17(6), 18(g), 18(h)
Compendium of Guidelines for Marketing Authorization of Medical Devices, Diagnostics and Laboratory EquipmentNo Government Gazette number (TMDA guideline document)June 2024Part I §3.3.3 (renewal dossier), §5.1 (validity and the three conditions)
Public Notice — Notice on Submission of Biennial PMS ReportsTMDA public notice17 August 2026Full text (citing regulation 17(3))

3. Expert insights

Insight 1: GN 315 says 5 years and the Compendium adds 3 years — the two rules do not conflict, but companies tend to remember only one of them.

Regulation 17(1) of GN 315 addresses the “full registration certificate under regulation 14(1)(a)” and states a validity of 5 years. Notification (listing) does not fall within the scope of certificates issued under regulation 14(1)(a); its validity is set separately at 3 years by Part I §5.1. Therefore 5 years for the registration certificate and 3 years for a listing approval are two parallel rules, not a contradiction. A portfolio that mixes registered and listed products runs on two different clocks, and any single-calendar assumption will eventually produce a missed expiry.

Insight 2: The 90 days for renewal and the 90-day grace period are two independent mechanisms and must not be added up into “180 days”.

Regulation 17(4) requires the renewal application to be submitted at least 90 days before expiry. Regulation 17(5) provides that the “grace period for renewal shall extend to 90 days after the specified expiry date”. Regulation 17(6) goes further: a defaulting holder after the grace period expires must pay a penalty under the current fee regulations. In other words, late renewal is not prohibited, but it is penalised, and the legal status of the certificate during the grace period should be confirmed with TMDA.

Insight 3: Of the five renewal dossier items, the fourth (PMS reports) is the new pressure point introduced in 2026.

Part I §3.3.3 requires a renewal application to include: a) a summary of changes made to the device since registration (both approved and pending changes must be reported); b) the device specification and certificate of batch analysis; c) product information, including label artwork or mock-up and the instructions for use or user manual; d) post-market surveillance reports; e) 2 samples of the same batch in commercial packaging. TMDA issued a dedicated notice on 17 August 2026 stressing the PMS reporting obligation, which effectively turns item d) of the renewal dossier into an ongoing annual activity rather than a renewal-week scramble.

Insight 4: Unpaid retention fees, missing PMS reports and wilful failure to report adverse effects are three independent routes to losing the certificate.

Regulation 18 lists nine grounds for suspension or cancellation. Among them, (g) failure to pay the prescribed retention fee on time, (h) failure to submit PMS reports as required, and (i) wilful and without reasonable excuse failure to submit adverse effect reports, are the three most commonly triggered by licence holders. Their common feature is that they have nothing to do with product quality — they are purely administrative omissions. That makes them predictable and entirely avoidable with a compliance calendar.

4. Practical recommendations

  1. Build a certificate calendar: set expiry dates at 5 years for registrations and 3 years for listings, and trigger the renewal process 90 days in advance.
  2. Do not rely on the grace period. It exists, but regulation 17(6) clearly requires a penalty, and the legal status of the certificate during that window is not self-evident.
  3. Assemble the renewal dossier 6 months ahead, in particular the summary of changes since registration — it must cover both approved and pending changes, which requires a complete change log as support.
  4. Make PMS reporting and the retention fee fixed annual actions rather than renewal-week catch-up tasks; the 17 August 2026 notice shows TMDA is actively policing this obligation.

5. Verification checklist

  • □ Confirmed the certificate type and validity: registration 5 years, listing 3 years.
  • □ Renewal started at least 90 days before expiry.
  • □ Aware that the grace period is 90 days after expiry and that a penalty applies for late renewal.
  • □ All five renewal dossier items ready, including the change summary (covering pending changes) and 2 samples of the same batch in commercial packaging.
  • □ Status of the two annual actions — retention fee payment and PMS reporting — confirmed.

Regulatory information verified as of 29 October 2026. All provisions cited in this document were checked against the official published texts of TMDA (GN. No. 315, regulations 17 and 18; the June 2024 Compendium of Guidelines, Part I §3.3.3 and §5.1; the TMDA public notice of 17 August 2026), and will be re-checked when the regulations are updated.

  • Tanzania local resources: licensed Local Responsible Person (LRP) and distributor resources can be coordinated to cover online submission, sample delivery, quality audit cooperation and port clearance.
  • Service capabilities: classification determination, registration and notification pathway selection, technical documentation (CSDT/STED) preparation and localization, GMDN and grouping strategy, clinical evidence organization, software and AI device submissions, change management, vigilance and PMS reporting, annual retention fees and renewal management.
  • Contact: hito.lin@grzan.cn; website www.grzan.cn.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail